| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -196.01 M CHF | -116.59 M CHF | -42.78 M CHF | -55.89 M CHF | -611071 CHF | — |
| Depreciation & Amortization | 2.62 M CHF | 1.38 M CHF | 370316 CHF | 164783 CHF | — | — |
| Stock-Based Compensation | 12.90 M CHF | 7.28 M CHF | 7.11 M CHF | 9.65 M CHF | — | — |
| Capital Expenditures | 35000 CHF | 519520 CHF | 284634 CHF | 16009 CHF | — | — |
| Cash Flow from Investing | 202.99 M CHF | -205.60 M CHF | -25.18 M CHF | -32.34 M CHF | — | — |
| Cash Flow from Financing | 146.00 M CHF | 51.31 M CHF | 479.70 M CHF | 119.69 M CHF | -58063 CHF | — |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | 50 CHF | 0 CHF | 0 CHF | — | — |
| Free Cash Flow | -196.04 M CHF | -117.11 M CHF | -43.06 M CHF | -55.91 M CHF | — | — |
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing next-level therapies for serious inflammatory diseases. The company targets over-expression of interleukins IL-17A and IL-17F, which drive conditions such as psoriasis, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). These chronic diseases significantly impair patients' quality of life, highlighting critical unmet medical needs. MoonLake Immunotherapeutics innovates through its lead candidate, Sonelokimab, a therapy designed to transform outcomes in these areas. The company sponsors innovative global research and ambitious Phase 3 clinical programs for hidradenitis suppurativa and psoriatic arthritis, leveraging unrivaled expertise to elevate treatment standards. Founded by Jorge Santos da Silva, who serves as Chief Executive Officer, MoonLake applies stellar science to address inflammatory diseases where current solutions fall short, positioning it as a key player in advancing biopharmaceutical solutions for dermatological and rheumatological disorders.